Organon OGN Other Biosimilars — Revenue

Other product segments

Similar metrics at other companies

BIIBBiosimilars — Total Revenue

$152.8M-15.9%

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

URIServiceand Other Revenues — Revenue

$101M+6.3%

FLYWPlatform And Other Revenues — Revenue

$31.85M+1.7%

FAQ

What is Organon's other biosimilars — revenue?

Organon (OGN) reported other biosimilars — revenue of $24M in Q1 2026.

How has Organon's other biosimilars — revenue changed year-over-year?

Organon's other biosimilars — revenue increased by 380.0% year-over-year, from $5M to $24M.

What is the long-term trend for Organon's other biosimilars — revenue?

Over 2 years (2021 to 2025), Organon's other biosimilars — revenue has grown at a -19.6% compound annual growth rate (CAGR), from $51M to $33M.

What does other biosimilars — revenue mean?

This metric represents the total net sales generated from the company's portfolio of biosimilar products categorized outside of its primary therapeutic focus areas. It reflects the market demand and commercial performance of secondary biosimilar assets within the broader pharmaceutical segment. Tracking this revenue stream helps investors evaluate the contribution of niche or non-core biosimilar offerings to the company's overall top-line growth.